C/EBPα deregulation as a paradigm for leukemogenesis. Leukemia 2017 Nov;31(11):2279-2285
Date
07/20/2017Pubmed ID
28720765Pubmed Central ID
PMC8197657DOI
10.1038/leu.2017.229Scopus ID
2-s2.0-85032623277 (requires institutional sign-in at Scopus site) 56 CitationsAbstract
Myeloid master regulator CCAAT enhancer-binding protein alpha (C/EBPα) is deregulated by multiple mechanisms in leukemia. Inhibition of C/EBPα function plays pivotal roles in leukemogenesis. While much is known about how C/EBPα orchestrates granulopoiesis, our understanding of molecular transformation events, the role(s) of cooperating mutations and clonal evolution during C/EBPα deregulation in leukemia remains elusive. In this review, we will summarize the latest research addressing these topics with special emphasis on CEBPA mutations. We conclude by describing emerging therapeutic strategies to restore C/EBPα function.
Author List
Pulikkan JA, Tenen DG, Behre GAuthor
John A. Pulikkan PhD Assistant Professor in the Cell Biology, Neurobiology and Anatomy department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCCAAT-Enhancer-Binding Protein-alpha
Hematopoietic Stem Cells
Humans
Leukemia, Myeloid, Acute
Mutation